Merck KGaA is allocating over €300 million ($321.8 million) to build a new research building at its headquarters in Darmstadt, Germany to study technologies for its life science business.
By 2027, the 18,000-square-meter site will host 550 workers, who will drive investigations into manufacturing antibodies and mRNA applications like recombinant proteins and viral vectors, as well as finding improvements to the mRNA value chain, according to a Thursday press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.